Novo Nordisk is facing a massive wave of generic competitors to its injectable formulations of GLP-1 agonist semaglutide, used to treat diabetes and obesity, as a key patent in India is due to expire ...
AI Quick Read MUMBAI: A day after semaglutide lost patent protection in India, top drugmakers including Dr Reddy’s, Sun Pharma, and Zydus Lifesciences launched generic versions priced 50-90% below the ...
The patent for semaglutide, the drug used in major weight-loss medications like Wegovy and Ozempic has expired. The end of the patent — held by Danish pharmaceutical giant Novo Nordisk — opens the ...
To learn more about the CNBC CFO Council, visit cnbccouncils.com/cfo Nearly half of U.S. generic prescriptions originate in India, which relies on the Strait of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results